GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2007

Bio-Rad Acquires DiaMed For Over $391M

  • Bio-Rad Laboratories plans to acquire DiaMed Holding for CHF 477 million, or approximately $391.48, through a definitive agreement. This price covers 77.7% of DiaMed’s outstanding shares.

    DiaMed holds approximately 9.6% of its outstanding shares as treasury shares. After the closing of this transaction, Bio-Rad reports that it will conduct a tender offer to acquire the remaining 12.7% outstanding shares.

    “DiaMed has an outstanding reputation for quality products and customer care,” reports John Goetz, Bio-Rad vp and group manager, clinical diagnostics. “We believe this portfolio of products will fit in well with Bio-Rad’s existing diagnostics business.”

    DiaMed develops, manufactures, and markets a complete line of reagents and instruments used in blood typing and screening. The company has annual sales of approximately $200 million to hospitals, clinical laboratories, and blood banks in more than 100 countries, according to Bio-Rad.

    Bio-rad expects to close the acquisition later this year.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?